Clinical Trial to Evaluate the Efficacy and Safety of D064 and D701 Combination Therapy
NCT ID: NCT05526703
Last Updated: 2022-11-28
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE3
108 participants
INTERVENTIONAL
2022-09-28
2023-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Clinical Trial to Evaluate the Efficacy and Safety of D064 and D702 Combination Therapy
NCT05931224
Clinical Trial to Evaluate the Efficacy and Safety of D064 and D702 Combination Therapy Versus D064 or D702 Monotherapy
NCT06121518
Phase III Study to Evaluate the Efficacy and Safety of AD-209
NCT06348576
A Study to Evaluate the Efficacy and Safety of BR1015 Combination Therapy
NCT05878561
A Study to Evaluate the Efficacy and Safety of AD-224
NCT06291207
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Experimental Group
D064, D701, placebo of D012
Experimental Group Subjects assigned to this group are treated with D064, D701, placebo of D012
Comparator Group
D012, placebo of D064, placebo of D701
Comparator Group Subjects assigned to this group are treated with D012, placebo of D064, placebo of D701
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
D064, D701, placebo of D012
Experimental Group Subjects assigned to this group are treated with D064, D701, placebo of D012
D012, placebo of D064, placebo of D701
Comparator Group Subjects assigned to this group are treated with D012, placebo of D064, placebo of D701
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Subjects who have voluntarily decided to participate in this clinical trial and signed ICF.
Exclusion Criteria
2. Subjects who require combination administration of antihypertensive drugs other than clinical trial drugs during the clinical trial participation period
3. Subjects with hypersensitivity or history of clinical trial drugs and similar drugs
4. Subjects who are required to administer a combination of prohibited drugs specified in this plan during the clinical trial participation period
5. Subjects with a history of drug or alcohol abuse or suspected patient within 24 weeks as of the time of screening
6. Subjects who received other clinical trial drugs within 4 weeks of screening visit.
7. Pregnant women, lactating women, or Subjects who do not agree to use appropriate contraception during the clinical trial period and for two weeks after the end of administration of the last clinical trial drug
8. Subjects who are unable to participate in this clinical trial at the discretion of the investigator.
19 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Chong Kun Dang Pharmaceutical
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Samsung Medical Center
Seoul, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Seung Hyuk Choi
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
A30_14HT2209
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.